Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Wednesday, setting a price target of $144, which is approximately 20.64% above the present share price of $119.36.
Divan expects Biohaven Pharmaceutical Holding Co to post earnings per share (EPS) of -$2.63 for the fourth quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Biohaven Pharmaceutical Holding Co, with an average price target of $152.2.
The analysts price targets range from a high of $177 to a low of $111.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $135.74 million and a net profit of -$139.95 million. The company's market cap is $7.82 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.3% and a 47.81% success rate.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.